<DOC>
	<DOCNO>NCT02070744</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy VX-661in combination ivacaftor subject cystic fibrosis ( CF ) homozygous F508del CFTR ( cystic fibrosis transmembrane conductance regulator ) mutation</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy VX-661 Combination With Ivacaftor Subjects With Cystic Fibrosis , Homozygous F508del-CFTR Mutation With Open-Label Expansion</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous F508del CFTR mutation FEV1 ≥40 % ≤90 % predict normal age , sex , height Stable CF disease judge investigator History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject Pregnant nursing female : Females childbearing potential must negative pregnancy test screen Day 1 Sexually active subject reproductive potential willing follow contraception requirement The subject close relative subject investigator sub investigator , research assistant , pharmacist , study coordinator , staff directly involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>CF</keyword>
</DOC>